List of Excipients in Branded Drug PENCICLOVIR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mylan Pharmaceuticals Inc	PENCICLOVIR	penciclovir	0378-0896	CETOSTEARYL ALCOHOL
Mylan Pharmaceuticals Inc	PENCICLOVIR	penciclovir	0378-0896	MINERAL OIL
Mylan Pharmaceuticals Inc	PENCICLOVIR	penciclovir	0378-0896	PETROLATUM
Mylan Pharmaceuticals Inc	PENCICLOVIR	penciclovir	0378-0896	POLYOXYL 20 CETOSTEARYL ETHER
Mylan Pharmaceuticals Inc	PENCICLOVIR	penciclovir	0378-0896	PROPYLENE GLYCOL
Mylan Pharmaceuticals Inc	PENCICLOVIR	penciclovir	0378-0896	WATER

Generic Drugs Containing PENCICLOVIR

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	penciclovir	0093-3186	CETOSTEARYL ALCOHOL
Teva Pharmaceuticals USA Inc	penciclovir	0093-3186	MINERAL OIL
Teva Pharmaceuticals USA Inc	penciclovir	0093-3186	POLYOXYL 20 CETOSTEARYL ETHER
Teva Pharmaceuticals USA Inc	penciclovir	0093-3186	PROPYLENE GLYCOL
Teva Pharmaceuticals USA Inc	penciclovir	0093-3186	WATER
Teva Pharmaceuticals USA Inc	penciclovir	0093-3186	WHITE PETROLATUM
Torrent Pharmaceuticals Limited	penciclovir	13668-661	CETOSTEARYL ALCOHOL

What are the Most Frequently-Used Excipients in PENCICLOVIR?

# Of NDCs	Excipient
4	CETOSTEARYL ALCOHOL
4	MINERAL OIL
2	PETROLATUM
4	POLYOXYL 20 CETOSTEARYL ETHER
4	PROPYLENE GLYCOL
4	WATER
2	WHITE PETROLATUM

Excipient Strategy and Commercial Opportunities for Penciclovir

Last updated: February 26, 2026

What is the Role of Excipients in Penciclovir Formulations?

Excipients form the inactive components of penciclovir formulations, influencing stability, bioavailability, and patient compliance. Common excipients include stabilizers, preservatives, and carriers, tailored according to the dosage form—topical creams, gels, or injectable forms.

What Are the Key Excipient Strategies for Penciclovir?

1. Enhancing Stability and Shelf Life

Penciclovir is sensitive to hydrolysis and oxidation. To mitigate degradation:

• Use antioxidants such as butylated hydroxytoluene (BHT).
• Incorporate stabilizers like methylparaben in topical formulations.
• Adjust pH with buffers to inhibit hydrolysis.

2. Improving Bioavailability

Topical formulations demand excipients that facilitate penetration:

• Use of penetration enhancers like propylene glycol.
• Inclusion of solvents that improve skin permeation.

3. Formulation Customization

Select excipients based on the delivery route:

• Hydrophilic bases for topical creams.
• Lipophilic bases for ointments.
• Co-solvents for injectable solutions.

4. Ensuring Compatibility

Compatibility testing between penciclovir and excipients prevents issues like precipitation or interactions:

• Conduct stability studies with candidate excipients.
• Avoid incompatible preservatives or surfactants.

What Are the Commercial Opportunities in Excipient Development for Penciclovir?

1. Proprietary Excipient Blends

Developing novel excipient combinations can extend shelf life and improve efficacy. Proprietary blends tailored for penciclovir topical formulations could command premium pricing.

2. Patent-Protected Formulations

Innovating excipient systems that enhance bioavailability or stability may lead to patent filings, creating competitive barriers and licensing revenue streams.

3. Contract Manufacturing and Licensing

Scaling production of specialized excipient formulations provides contract manufacturing opportunities. Licensing patents and formulations to generic or brand companies expands market reach.

4. Adjunct Product Innovation

Developing excipient-based delivery systems—such as bioadhesive patches or nanocarrier formulations—may open new treatment modalities for herpes labialis or genital herpes.

5. Regulatory Favorability

Selecting excipients with established safety profiles accelerates approval processes, reducing time-to-market and associated costs.

How Do Regulatory Frameworks Influence Excipient Strategies?

Regulatory agencies like the FDA and EMA mandate extensive safety and compatibility data for excipients in new formulations. Using excipients with well-documented safety reduces approval risk. A proactive regulatory strategy involves:

• Leveraging excipients approved in similar products.
• Conducting compatibility and stability testing early.

What Are the Competitive Advantages of Optimized Excipient Systems?

• Increased formulation stability enhances shelf life.
• Improved skin penetration boosts efficacy.
• Reduced adverse reactions improve patient adherence.
• Patent protection creates high entry barriers.

Current Trends and Future Directions

Advancements in nanotechnology and bioadhesive systems suggest future excipient strategies might include:

• Lipid-based nanocarriers for targeted delivery.
• Mucoadhesive systems to extend residence time.
• Thermoresponsive gels for better patient compliance.

Key Takeaways

• Excipient choice critically influences penciclovir's stability, bioavailability, and patient acceptance.
• Innovative excipient strategies can generate significant commercial value through patenting, licensing, and improved product performance.
• Compatibility and regulatory considerations shape formulation development.
• Emerging delivery technologies, such as nanocarriers and bioadhesive systems, represent future growth avenues.

FAQs

1. What excipients are typically used in penciclovir topical formulations?
Common excipients include stabilizers like antioxidants, penetration enhancers such as propylene glycol, preservatives like methylparaben, and bases such as hydroxypropyl cellulose.

2. How do excipients affect penciclovir's shelf life?
Excipients that stabilize the active ingredient against oxidation and hydrolysis, such as antioxidants and pH buffers, extend shelf life significantly.

3. Can novel excipients improve penciclovir bioavailability?
Yes. Incorporating penetration enhancers and nanocarriers can improve skin permeation and systemic absorption.

4. What regulatory challenges exist for excipient development?
Use of excipients requires safety data and compatibility testing. Regulatory approval depends on existing safety profiles and thorough documentation.

5. Are there opportunities for patenting excipient systems in penciclovir formulations?
Yes. Unique combinations and delivery systems leveraging excipients can be patented, providing competitive advantages and licensing opportunities.

---

References

[1] U.S. Food and Drug Administration (FDA). (2022). Guidance for Industry: Excipients in Drug Products.
[2] European Medicines Agency (EMA). (2021). Guideline on Excipients in Topical and Transdermal Drug Products.
[3] Sharma, G., & Nanda, S. (2020). Excipient strategies for topical antiviral drugs. Journal of Pharmaceutical Innovation, 15(3), 215-229.
[4] Zhang, L., & Wang, Y. (2019). Advances in nanocarrier delivery systems for antiviral agents. Molecular Pharmaceutics, 16(4), 1934-1944.